CAPR
Capricor Therapeutics IncNASDAQHEALTHCAREBIOTECHNOLOGY
Key Statistics
Market Cap
$1.82B
P/E Ratio
—
EPS
$-2.26
Beta
0.48
52W High
$40.37
52W Low
$4.30
50-Day MA
$27.38
200-Day MA
$15.52
Dividend Yield
—
Profit Margin
0.00%
Forward P/E
78.74
PEG Ratio
0.38
About Capricor Therapeutics Inc
Capricor Therapeutics, Inc., a biotechnology company, focuses on the development of transformative cell- and exosome-based therapies for the treatment and prevention of a broad spectrum of diseases. The company is headquartered in Beverly Hills, California.
Fundamentals
| Revenue (TTM) | $11.13M |
| Gross Profit (TTM) | $-84.45M |
| EBITDA | $-106.25M |
| Operating Margin | 0.00% |
| Return on Equity | -46.60% |
| Return on Assets | -25.70% |
| Revenue/Share (TTM) | $0.24 |
| Book Value | $5.33 |
| Price-to-Book | 6.04 |
| Price-to-Sales (TTM) | 124.43 |
| EV/Revenue | 141.52 |
| EV/EBITDA | -2.73 |
| Quarterly Earnings Growth (YoY) | 0.00% |
| Quarterly Revenue Growth (YoY) | -7.90% |
| Shares Outstanding | $57.51M |
| Float | $48.56M |
| % Insiders | 13.36% |
| % Institutions | 54.05% |
Historical Volatility
HV 10-Day
67.03%
HV 20-Day
66.46%
HV 30-Day
71.62%
HV 60-Day
73.04%
HV Rank
—
Volatility is currently contracting
Analyst Ratings
Consensus ($53.90 target)
2
Strong Buy8
BuyData last updated: 4/10/2026